| Name | Title | Contact Details |
|---|
Headquartered in Jacksonville, FL, Healogics is the nation`s largest provider of advanced wound care services. Healogics and its affiliated companies manage a network of Wound Care Centers® through-out the United States and the United Kingdom. Healogics technology-enabled wound care model supports the critical connection between patients with chronic wounds and multi-disciplinary teams for continuous, collaborative, patient-centered care.
At Transitions Optical we help people live more vibrant lives by enhancing their vision and the way they perceive light. We were the first to successfully commercialise a plastic photochromic lens in 1990 and our talented people continue to make significant advances in colour science and lens materials, creating a better photochromic experience that`s available to more people. Through our partnerships with optical industry leaders, we offer adaptive solutions in the widest selection of designs and materials, covering hundreds of lens combinations. Our industry leading eyeglass brands are well known; Transitions® Signature®, Transitions® Vantage® and Transitions® XTRActive®. And we don`t stop there; we also make adaptive sunwear and motorcycle helmet shields. Transitions Optical is part of the Essilor Group.
At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible. PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb®. NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways. NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns. We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.
MDC Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Premise Corporation is a Farmington, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.